잠시만 기다려 주세요. 로딩중입니다.

Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion

Cancer Research and Treatment 2021년 53권 2호 p.291 ~ 300
유창훈, 오충렬, 김승태, 배우균, 최혜진, 오도연, 이명아, 류백열,
소속 상세정보
유창훈 ( Yoo Chang-Hoon ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
오충렬 ( Oh Chung-Ryul ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
김승태 ( Kim Seung-Tae ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
배우균 ( Bae Woo-Kyun ) - Chonnam National University Medical School Department of Internal Medicine
최혜진 ( Choi Hye-Jin ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Internal Medicine
오도연 ( Oh Do-Youn ) - Seoul National University College of Medicine Seoul National University Hospital Department of Internal Medicine
이명아 ( Lee Myung-Ah ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
류백열 ( Ryoo Baek-Yeol ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology

Abstract


Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients. We here provide a consensus review of the diagnosis, staging and systemic treatment of Korean GEP-NET patients. Systemic therapy options and the current Korean expert consensus on these treatments, including somatostatin analogs, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide treatments, and cytotoxic chemotherapies are addressed.

키워드

Neuroendocrine tumor; Lanreotide; Octreotide; Everolimus; Sunitinib; Peptide receptor radionuclide therapy; Capecitabine; Temozolomide

원문 및 링크아웃 정보

 

등재저널 정보